Immunotherapy Drugs Market by Drug Type (Checkpoint Inhibitors, Interferons, Interleukins, Monoclonal Antibodies, Vaccines, Others), Disease Type (Autoimmune and Inflammatory Diseases, Cancer, Infectious Diseases, Others) and Forecast 2017-2021

Immunotherapy Drugs Market by Drug Type (Checkpoint Inhibitors, Interferons, Interleukins, Monoclonal Antibodies, Vaccines, Others), Disease Type (Autoimmune and Inflammatory Diseases, Cancer, Infectious Diseases, Others) and Forecast 2017-2021

Immunotherapy drugs boosts the body’s natural defenses to fight various diseases. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work either by stopping or slowing the growth of diseased cells, stopping disease from spreading to other parts of the body, or helping the immune system work better at destroying affected cells. Immune checkpoint inhibitors are drugs, often made of antibodies that unleash an immune system attack on cancer cells. Three checkpoint inhibitors have received rapid approval from the U.S. Food and Drug Administration for cancer, including ipilimumab (Yervoy), pembrolizumab (Keytruda), and nivolumab (Opdivo). Cell-based immunotherapies are effective for some cancers. Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Antimicrobial immunotherapy, which includes vaccination, involves activating the immune system to respond to an infectious agent.

The global immunotherapy drugs market segmentation is based on drug type (checkpoint inhibitors, interferons, interleukins, monoclonal antibodies, vaccines, others), and disease type (autoimmune and inflammatory diseases, cancer, infectious diseases, others).

The global immunotherapy drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global immunotherapy drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global immunotherapy drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global immunotherapy drugs market and profiled in this report include Amgen Inc., F. Hoffmann-La Roche AG, Glaxosmithkline Plc, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Immunotherapy Drugs Market

1. Drug Type
1.1. Checkpoint Inhibitors
1.2. Interferons
1.3. Interleukins
1.4. Monoclonal Antibodies
1.5. Vaccines
1.6. Others

2. Disease Type
2.1. Autoimmune and Inflammatory Diseases
2.2. Cancer
2.3. Infectious Diseases
2.4. Others

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Latin America (Brazil, Mexico, Rest of LA)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World (Middle East & Africa)

4. Company Profiles
4.1. Amgen Inc.
4.2. F. Hoffmann-La Roche AG
4.3. Glaxosmithkline Plc
4.4. Johnson & Johnson
4.5. Merck & Co., Inc.
4.6. Novartis International AG

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*